FORM 4

to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C. 20549
-------------	------------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Check this box if no longer subject

OMB APPROVAL										
OMB Number: 3235-02										
Estimated average burden										
hours per response	. 0.5									

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 Instruction 1(b).

1. Name and Address of Reporting Person* SARAN ATUL						2. Issuer Name and Ticker or Trading Symbol Emergent BioSolutions Inc. [EBS]									ck all app Direct	,	ng Per	rson(s) to Is 10% Ov Other (s	wner
(Last) 400 PRO SUITE 4	3. Date of Earliest Transaction (Month/Day/Year) 02/08/2023								· >	below	below) below) EVP, Chief Strat & Dev Officer								
(Street) GAITHERSBURG MD 20879 (City) (State) (Zip)						4. If Amendment, Date of Original Filed (Month/Day/Year)							Line	ndividual or Joint/Group Filing (Check Applicable e) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
		Table	I - No	n-Deriva	tive S	Secu	rities	Acq	uired,	Dis	posed of	, or E	Bene	ficial	ly Own	ed			
1. Title of Security (Instr. 3) 2. Transact Date (Month/Day					Execution Date,			Date,	Transaction Disposed Of (Code (Instr. 5)			s Acquired (A) or Of (D) (Instr. 3, 4 and			5. Amount of Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	Amount	(A) (D)	(A) or (D) Pri		Transa	Transaction(s) (Instr. 3 and 4)			(111541. 4)				
Common Stock 02/08/2				2023			Α		95(1)	A		\$ <mark>0</mark>	90	90,877		D			
Common Stock 02/08/2				2023		F		2,051(2)	Г) [313.25	5 88	88,826		D				
		Tal									osed of, convertib				Owned	t	•		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	if any	med 4. In Date, Transa Code (I Day/Year) 8)			of Deriv Secu Acqu (A) o Dispo	r osed) r. 3, 4	6. Date Exerc Expiration Da (Month/Day/\)		ate	7. Title and Amount of Securities Underlying Derivative Security (In 3 and 4)		S (I	. Price of Perivative ecurity nstr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	y	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
	Code V		v	(A)	(D)	Date Exercis	able	Expiration Date	Title	Amor or Numi of Share	oer								

Explanation of Responses:

1. Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to adjusted net income as a percentage of total GAAP revenue for the 2022 fiscal year, as certified by the Compensation Committee following the performance period. On February 08, 2023, the final certification date, the Compensation Committee certified the achievement of the 2020-2022 PSUs at a payout factor of 101.67% of target resulting in the actual award of 5,792 shares of common stock, which is in excess of the 5,697 shares previously reported on February 25, 2020.

Remarks:

/s/ Jennifer Lynn Fox, Attorney-in-fact

02/10/2023

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{2.} Represents shares of common stock withheld to pay taxes.